Maryland researchers are building miniature human brain tissue in the lab, hoping to replace the animal tests that currently slow down drug development for Alzheimer's disease and neurodevelopmental disorders like autism.

The project, funded by a $2.86 million NIH grant, combines lab-grown 3D brain tissue, known as organoids, with electrode sensors and AI analysis to measure how human neural tissue learns and remembers. The goal is to create a testing platform that can do what animal behavioral studies do now, but using human cells instead.

The stakes are real. Rates of neurodevelopmental disorders and Alzheimer's disease are climbing, yet the drug development pipeline keeps failing. One reason: the animal models researchers rely on don't always predict how human brains respond to drugs or chemical exposures. Thousands of chemicals also remain untested for neurological harm simply because current methods can't keep up.

The platform, called DROIDP, will grow organoids from human stem cells, including cells donated by patients with SYNGAP1-related disorders (a rare genetic cause of intellectual disability) and Alzheimer's disease. Researchers will then expose those organoids to drugs and chemicals, measuring electrical activity and other signals to see how the tissue responds. Artificial intelligence will help match those lab results to patterns seen in actual patients, building toward reliable biomarkers for brain function.

The interdisciplinary team spans neuroscience, toxicology, engineering, data science, and neuroethics. The practical payoff, if the platform works as intended, would be faster and more accurate screening of drug candidates and potentially hazardous chemicals, without waiting on animal studies.

The research is expected to produce a standardized, reproducible organoid platform with performance benchmarks that other labs and regulators could eventually adopt for routine testing.